Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study

References

• Brooks BR, Sanjak M, Belden D, Juhasz-Poscine K, Waclawik A. Natural history of amyotrophic lateral sclerosis: impairment, disability, handicap. Amyotrophic Lateral Sclerosis, RH Brown, V Meininger, M Swash. Martin Dunitz, London 2000; 31–58
   Google Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002; 418: 41–9
   PubMed Web of Science ®Google Scholar
• Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA, et al. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet. 2004; 363: 1432–7
   PubMed Web of Science ®Google Scholar
• Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B. Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci. 2003; 100: 1364–9
   PubMed Web of Science ®Google Scholar
• Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003; 302: 113–7
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Boillee S, Roberts EA, Garcia ML, McAlonis-Downes M, Mikse OR, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci. 2008; 105: 7594–9
   PubMed Web of Science ®Google Scholar
• Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006; 312: 1389–92
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci. 2006; 103: 16021–6
   PubMed Web of Science ®Google Scholar
• Corti S, Locatelli F, Donadoni C, Guglieri M, Papadimitriou D, Strazzer S, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain. 2004; 127: 2518–32
   PubMed Web of Science ®Google Scholar
• Ende N, Weinstein F, Chen R, Ende M. Human umbilical cord blood effect on SOD mice (amyotrophic lateral sclerosis). Life Sci. 2000; 67: 53–9
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Willing AE, Zigova T, Saporta S, Justen EB, Lane JC, et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res. 2003; 12: 255–70
   PubMedGoogle Scholar
• Solomon JN, Lewis CA, Ajami B, Corbel SY, Rossi F, Krieger C. Origin and distribution of bone marrow derived cells in the central nervous system in a mouse model of amyotrophic lateral sclerosis. Glia. 2006; 53: 744–53
   PubMed Web of Science ®Google Scholar
• Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res. 2001; 10: 913–5
   PubMedGoogle Scholar
• Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Oliveri C, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotr Later Scler. 2003; 4: 158–61
   PubMed Web of Science ®Google Scholar
• Mazzini L, Maresch K, Ferrero I, Vassallo E, Oliveri G, Nasuelli N, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci. 2008; 265: 78–83
   PubMed Web of Science ®Google Scholar
• Appel SH, Engelhardt JL, Henkel JS, Sikols L, Beers DR, Yen AA, et al. Haematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008; 71: 1326–34
   PubMed Web of Science ®Google Scholar
• Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996; 88: 1907–29
   PubMed Web of Science ®Google Scholar
• Hubel K, Engert A. Clinical applications of granulocyte-colony stimulating factor: an update and summary. Ann Hematol. 2003; 82: 207–13
   PubMed Web of Science ®Google Scholar
• Schnieder A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The haematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005; 115: 2083–98
   PubMed Web of Science ®Google Scholar
• Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte-colony stimulating factor after focal cerebral ischaemia. Stroke. 2003; 34: 745–51
   PubMed Web of Science ®Google Scholar
• Meur M, Pitzer C, Teismann P, Kruger C, Goricke B, Laage R, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem. 2006; 97: 675–86
   PubMed Web of Science ®Google Scholar
• Hartung T. Anti-inflammatory effects of granulocyte-colony stimulating factor. Curr Opin Hematol. 1998; 5: 221–5
   PubMedGoogle Scholar
• Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS: a dual role?. Exp Neurol. 2004; 187: 1–10
   PubMed Web of Science ®Google Scholar
• Weydt P, Weiss MD, Moller T, Carter GT. Neuroinflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs. 2002; 3: 1720–4
   PubMedGoogle Scholar
• Pitzer C, Kruger C, Plaas C, Kirsch F, Dittgen T, Muller R, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain. 2008; 131: 3335–47
   PubMed Web of Science ®Google Scholar
• Cashman N, Tan LY, Krieger C, Madler B, Mackay A, Mackenzie I, et al. Pilot study of granulocyte-colony stimulating factor (G-CSF): mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve. 2008; 37: 620–5
   PubMed Web of Science ®Google Scholar
• Zhang, Y, Wang, L, Fu, Y, Song, H, Zhao, H, Deng, M, , et al. Preliminary investigation of effect of granulocyte-colony stimulating factor on amyotrophic lateral sclerosis. Amyotroph Later Scler 2009, (Epub ahead of print)
   Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Later Scler Other Motor Neuron Disord. 2000; 1: 293–9
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessment of respiratory function. BDNF ALS Study group (Phase II/III). J Neurol Sci. 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Aid to the examination of the peripheral nervous system, Memorandum no. 45, Her Majesty's Stationery Office, London. 1976
   Google Scholar
• de Carvalho M, Scotto M, Lopes A, Swash M. Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle Nerve. 2003; 28: 630–3
   PubMed Web of Science ®Google Scholar
• Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K. Validity of the McGill Quality of Life questionnaire in the palliative care setting: a multicentre Canadian study demonstrating the importance of the existential domain. Palliat Med. 1997; 11: 3–20
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004; 63: 1933–5
   PubMed Web of Science ®Google Scholar
• Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007; 69: 776–84
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Veheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurology. 2007; 6: 1045–53
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 17–28
   PubMed Web of Science ®Google Scholar
• Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte-colony stimulating factor for acute ischaemic stroke: a randomized controlled trial. Can Med Assoc J. 2006; 174: 927–33
   PubMed Web of Science ®Google Scholar
• Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique patterns of haematopoietic cell mobilization induced by CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells. 2007; 25: 2158–66
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett S, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modelling ALS. PLoS ONE. 2007; 2: 1205
   PubMed Web of Science ®Google Scholar
• Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke. 2004; 35: 2385–9
   PubMed Web of Science ®Google Scholar